May 2 |
UPDATE 3-Novo Nordisk raises outlook fuelled by obesity drug demand
|
May 2 |
Novo Nordisk raises outlook fuelled by obesity drug demand
|
May 2 |
FOCUS-British pharmacies vie for weight-loss patients with drug price cuts
|
May 1 |
Eli Lilly 'On Its Way' To $1 Trillion Market Cap, Analysts Say: It's A 'Have' In A Sea Of 'Have Nots'
|
May 1 |
Eli Lilly Shoots Higher: It's Time To Be Cautious
|
May 1 |
Eli Lilly: The GLP-1 Wonder Continues, A Bullish Beat And Raise
|
May 1 |
Eli Lilly: Management Raises 2024 Guidance, Driven By GLP-1 Franchise
|
May 1 |
Danish Medicines Agency Says Type 2 Diabetes Patients Should Start Treatment With 'Cheaper' Drugs
|
May 1 |
Eli Lilly: Bloated Stock
|
May 1 |
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
|